Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POLESTAR phase IIa trial in HER2-negative gastric or gastroesophageal junction adenocarcinoma
2021-000150-26Phase 2Completed
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Aug 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and olaparib in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Institut für Klinische Krebsforschung. Primary endpoint: Overall survival rate at 1 year. Started Aug 2021; status: completed.
02
Drugs
pembrolizumabolaparib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2021-000150-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000150-26.